High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

Journal of Clinical Oncology

Volumn 13, Issue 2, 1995, Pages 424-429

  Smith, I E ^a   Walsh, G ^b   Jones, A ^b   Prendiville, J ^b   Johnston, S ^b   Gusterson, B ^b   Ramage, F ^b   Robertshaw, H ^b   Sacks, N ^b   Ebbs, S ^b   McKinna, J A ^b   Baum, M ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EDETATE CHROMIUM CR 51; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PYRIDOXINE; WARFARIN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; ERYTHEMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MASTECTOMY; NEPHROTOXICITY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0028890177     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1995.13.2.424     Document Type: Article

References (29)

1. Smith IE, Jones AL, O'Brien MER, et al: Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29a:1796-1799, 1993
2. Hortobagyi GN, Ames GR, Buzdar FC, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62:2507-2516, 1988
3. Anderson EDC, Forrest APM, Hawkins RA, et al: Primary systemic therapy for operable breast cancer. Br J Cancer 63:561-566, 1991
4. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
5. Jacquillat C, Weil M, Baillet F, et al: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66:119-129, 1990
6. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Ann Oncol 2:347-354, 1991
7. Powles TJ: A randomised trial of adjuvant versus neoadjuvant chemotherapy of operable breast cancer. Eur J Cancer 29a:574, 1993 (suppl 6)
8. Fisher B, Wickerham DL: Preoperative systemic therapy for the treatment of primary breast cancer, in Powles TJ, Smith IE (eds): Medical Management of Breast Cancer. London, England, Martin Dunitz, 1991, pp 281-286
9. Bonadonna G, Valagussa P, Brambilla C, et al: Preoperative chemotherapy in operable breast cancer. Lancet 341:1485, 1993
10. Findlay M, Cunningham D, Norman A, et al: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609-616, 1994
11. Jones AL, Smith IE, O'Brien MER, et al: Phase II study of continuous infusional 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: An active new regimen. J Clin Oncol 12:1259-1265, 1994
12. Haagensen CD, Stout AP: Carcinoma of the breast: Criteria of inoperability. Ann Surg 118:859-870, 1943
13. Miller AB, Hoogstraten B, Straquet M, et al: Reporting results of cancer treatment. Cancer 147:207-214, 1981
14. Fraile RJ, Baker LH, Burcker TR et al: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40:2223-2228, 1980
15. Balis FM, Hokenberg JS, Bleyer, WA: Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 8:202-232, 1983
16. Hansen R, Quebbeman E, Ausman R et al: Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: Results in 91 patients. J Surg Oncol 40:177-181, 1989
17. Hansen R, Quebbeman E, Beatty P et al: Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 10:145-149, 1987
18. Huan S, Padzur R, Singhakowinka A et al: Low-dose continuous 5-fluorouracil. Evaluation in advanced breast cancer. Cancer 63:419-422, 1989
19. Hansen RN: 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies. Cancer Invest 9:637-642, 1991
20. Anderson NR: 5-Fluorouracil: A reappraisal of optimal delivery in advanced breast cancer. J Infus Chemother 3:111-118, 1993
21. Lokich JJ, Ahlgren JD, Gullo JJ et al: A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 7:425-432, 1989
22. Lokich J, Bothe A, Fine N, Perri J: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565-2568, 1981
23. Lokich JJ, Moore C: Chemotherapy-associated palmar plantar erythroclysesthesia syndrome. Ann Intern Med 101:797-800, 1984
24. Scanlon KJ, Nee Dels C: Biochemical basis for cisplatinum and 5-fluorouracil synergism in human tumours. Proc Am Soc Clin Oncol 27:291, 1986 (abstr)
25. Fernandez-Hidalgo HO, Gonzalez F, Gil A, et al: 120 Hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol 12:397-410, 1989
26. Kolaric K, Roth A: Phase II clinical trial of cis-dichlordiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108-112, 1983
27. Mechl Z, Sopova B: CAP (cyclophosphamide, Adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 31:431-435, 1984
28. Sledge GW, Loehrer PJ, Roth BJ, et al: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814, 1988
29. Smith IE, Talbot DC: Cisplatin and its analogues in the treatment of advanced breast cancer: A review. Br J Cancer 65:787-793, 1992